| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911059 | Lung Cancer | 2015 | 7 Pages |
Abstract
Both the therapeutic efficacy in a metastatic mouse model of NSCLC and the extensive presence of the EDA domain of fibronectin in human NSCLC biopsies support the rational development of therapies based on the F8-IL2 immunocytokine for the treatment of NSCLC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sébastien Wieckowski, Teresa Hemmerle, Spasenja Savic Prince, Béatrice Dolder Schlienger, Sven Hillinger, Dario Neri, Alfred Zippelius,